Dana W J, Farthing K
Univ. of Texas, M.D. Anderson Cancer Ctr., Houston TX 77030, USA.
Pharm Pract Manag Q. 1998 Jul;18(2):23-31.
Biotechnology products have created therapy options in areas that have been historically limited. These improvements in patient care have resulted in a reappraisal of the emphasis placed on product acquisition costs and a movement toward evaluating the impact of the product on the entire health care system. Strategic planning for biotechnology products allows pharmacists to partner with the medical staff and financial/administrative representatives of the institution to measure clinical outcomes, estimate cost and revenue impact, document utilization, and promote cost-effective use of these new therapies to generate the maximum benefit for dollars expended.
生物技术产品在以往受限的领域创造了治疗选择。患者护理方面的这些改善导致了对产品购置成本重视程度的重新评估，并促使人们转向评估产品对整个医疗系统的影响。生物技术产品的战略规划使药剂师能够与医疗机构的医务人员以及财务/行政代表合作，以衡量临床结果、估计成本和收入影响、记录使用情况，并促进这些新疗法的成本效益使用，从而为所花费的资金创造最大效益。
